Johnson & Johnson’s Promising Pharmaceutical Developments Justify Buy Rating
Leerink Partners analyst David Risinger has maintained their bullish stance on JNJ stock, giving a Buy rating on November 14.Don't Miss our ...
Johnson & Johnson’s M&A Strategy in Cardiovascular Devices Supports Hold Rating
Analyst Larry Biegelsen from Wells Fargo maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price target ...